173 results
8-K
IMGN
Immunogen, Inc.
31 Jan 24
Submission of Matters to a Vote of Security Holders
4:12pm
and the Adjournment Proposal was not presented to the Company’s shareholders.
The completion of the Merger remains subject to the satisfaction of other
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
on January 11, 2024.
On January 29, 2024, the FCO approved the Merger unconditionally.
The completion of the Merger remains subject to the satisfaction … ; the satisfaction or waiver of the conditions precedent to the consummation of the Merger, including the ability to secure regulatory approvals
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
of the Merger remains subject to the satisfaction of other closing conditions, including the expiration or termination of any applicable waiting … to consummate the Merger on a timely basis or at all; the satisfaction or waiver of the conditions precedent to the consummation of the Merger, including
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
; the ability of the parties to consummate the Merger on a timely basis or at all; the satisfaction or waiver of the conditions precedent to the consummation
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
a termination fee pursuant to the Merger Agreement; the ability of the parties to consummate the Merger on a timely basis or at all; the satisfaction or waiver
DEFA14A
vinadjko
8 Jan 24
Additional proxy soliciting materials
4:12pm
8-K
kswe9
8 Jan 24
Other Events
4:11pm
DEFM14A
oz74zzqvtazx d42kv
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
vfjnp byh2grl
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
0323a84bv
21 Dec 23
Additional proxy soliciting materials
3:54pm
DEFA14A
w81ayi39t
30 Nov 23
Additional proxy soliciting materials
4:08pm
DEFA14A
EX-2.1
psrrkx460sgf4oz7w
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-99.1
432djdomu v2b0
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
bwc5mt
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
7i17f 9ocr
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
iwe4yv3 ppnr
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
e0g94t9ojunmqhdue
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-1.1
en86gxp256mczi
5 May 23
Entry into a Material Definitive Agreement
5:15pm
8-K
xtcrbxhbc9q 8e12pwzr
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
qm662q
5 May 23
Prospectus supplement for primary offering
4:49pm